ATE374602T1 - Orale kapselformulierung mit verbesserter physikalischer stabilität - Google Patents
Orale kapselformulierung mit verbesserter physikalischer stabilitätInfo
- Publication number
- ATE374602T1 ATE374602T1 AT02799287T AT02799287T ATE374602T1 AT E374602 T1 ATE374602 T1 AT E374602T1 AT 02799287 T AT02799287 T AT 02799287T AT 02799287 T AT02799287 T AT 02799287T AT E374602 T1 ATE374602 T1 AT E374602T1
- Authority
- AT
- Austria
- Prior art keywords
- physical stability
- improved physical
- capsule formulation
- oral capsule
- capsule
- Prior art date
Links
- 239000007963 capsule composition Substances 0.000 title 1
- 229940100691 oral capsule Drugs 0.000 title 1
- 239000002775 capsule Substances 0.000 abstract 3
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34243001P | 2001-12-21 | 2001-12-21 | |
| US10/324,954 US7011846B2 (en) | 2001-12-21 | 2002-12-20 | Oral capsule formulation with increased physical stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE374602T1 true ATE374602T1 (de) | 2007-10-15 |
Family
ID=26984706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02799287T ATE374602T1 (de) | 2001-12-21 | 2002-12-20 | Orale kapselformulierung mit verbesserter physikalischer stabilität |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7011846B2 (de) |
| EP (1) | EP1455763B1 (de) |
| JP (1) | JP2005531495A (de) |
| AT (1) | ATE374602T1 (de) |
| AU (1) | AU2002364212B2 (de) |
| CA (1) | CA2466868C (de) |
| DE (1) | DE60222803T2 (de) |
| ES (1) | ES2294197T3 (de) |
| WO (1) | WO2003055468A1 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60223254T2 (de) * | 2001-07-06 | 2008-08-14 | Penwest Pharmaceuticals Co. | Verzögert freisetzende formulierungen von oxymorphon |
| US8557291B2 (en) | 2002-07-05 | 2013-10-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
| US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| US7399488B2 (en) | 2002-07-05 | 2008-07-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| US8840928B2 (en) * | 2002-07-05 | 2014-09-23 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| US20050049210A1 (en) * | 2003-08-27 | 2005-03-03 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| CA2916869A1 (en) | 2004-06-12 | 2005-12-29 | Jane C. Hirsh | Abuse-deterrent drug formulations |
| US20080269161A1 (en) * | 2005-01-20 | 2008-10-30 | Seth Perry | Compositions and Methods Relating to Mitochondrial Hyperpolarization in Neurological Disease |
| US20070014847A1 (en) * | 2005-07-05 | 2007-01-18 | Ahmed Salah U | Coated capsules and methods of making and using the same |
| GB0523041D0 (en) * | 2005-11-11 | 2005-12-21 | Cyclacel Ltd | Combination |
| GB0526419D0 (en) * | 2005-12-23 | 2006-02-08 | Cyclacel Ltd | Formulation |
| DK1847258T4 (da) | 2006-04-13 | 2013-04-15 | Acino Pharma Ag | Partialglycerider som smøremiddel til farmaceutiske sammensætninger indeholdende thieno[3,2-c]pyridin-derivater |
| GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| CA2690490C (en) * | 2010-01-19 | 2012-06-26 | Accucaps Industries Limited | Pharmaceutical formulations of loratadine for encapsulation and combinations thereof |
| WO2012039768A2 (en) * | 2010-09-24 | 2012-03-29 | Texas Southern University | Itraconazole formulations |
| US9622981B2 (en) | 2011-11-17 | 2017-04-18 | Mylan Inc. | Liquid-filled hard gel capsule pharmaceutical formulations |
| US8633178B2 (en) | 2011-11-23 | 2014-01-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| WO2013149258A2 (en) | 2012-03-30 | 2013-10-03 | Charles Drew University of Medicine and Science | Compositions and methods for treating or preventing metabolic syndrome disorders |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20140271923A1 (en) | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
| EP3145489A1 (de) | 2014-05-22 | 2017-03-29 | TherapeuticsMD, Inc. | Natürliche kombinierte hormonersatzformulierungen und therapien |
| RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| WO2017205673A1 (en) | 2016-05-25 | 2017-11-30 | TSI Group Ltd. | Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules |
| US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| CN118078771B (zh) * | 2024-04-07 | 2024-09-27 | 广东润科生物科技有限公司 | 降血脂软胶囊及其生产工艺 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2906603A1 (de) * | 1979-02-21 | 1980-09-04 | Boehringer Mannheim Gmbh | N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel |
| US4339428A (en) * | 1980-08-18 | 1982-07-13 | Bristol-Myers Company | Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component |
| KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| GB8904182D0 (en) * | 1989-02-23 | 1989-04-05 | Glaxo Canada | Pharmaceutical compositions |
| IE61651B1 (en) * | 1990-07-04 | 1994-11-16 | Zambon Spa | Programmed release oral solid pharmaceutical dosage form |
| US5431916A (en) * | 1993-04-29 | 1995-07-11 | The Procter & Gamble Company | Pharmaceutical compositions and process of manufacture thereof |
| US5538737A (en) * | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
| FR2737121B1 (fr) * | 1995-07-27 | 1997-10-03 | Cl Pharma | Nouvelles formulations galeniques du fenofibrate et leurs applications |
| US5776957A (en) * | 1996-11-15 | 1998-07-07 | The University Of Kentucky Research Foundation | Nornicotine enantiomers for use as a treatment for dopamine related conditions and disease states |
| GB9724544D0 (en) * | 1997-11-21 | 1998-01-21 | Smithkline Beecham Plc | Novel Formulation |
| US20020032220A1 (en) * | 1997-11-21 | 2002-03-14 | Smithkline Beecham Plc | Formulations comprising dissolved paroxetine |
| US6174547B1 (en) * | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| CA2410683A1 (en) * | 2000-07-24 | 2002-01-31 | Pharmacia & Upjohn Company | Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
-
2002
- 2002-12-20 AT AT02799287T patent/ATE374602T1/de not_active IP Right Cessation
- 2002-12-20 ES ES02799287T patent/ES2294197T3/es not_active Expired - Lifetime
- 2002-12-20 JP JP2003556046A patent/JP2005531495A/ja active Pending
- 2002-12-20 AU AU2002364212A patent/AU2002364212B2/en not_active Ceased
- 2002-12-20 CA CA2466868A patent/CA2466868C/en not_active Expired - Fee Related
- 2002-12-20 DE DE60222803T patent/DE60222803T2/de not_active Expired - Lifetime
- 2002-12-20 WO PCT/US2002/041169 patent/WO2003055468A1/en not_active Ceased
- 2002-12-20 EP EP02799287A patent/EP1455763B1/de not_active Expired - Lifetime
- 2002-12-20 US US10/324,954 patent/US7011846B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60222803D1 (de) | 2007-11-15 |
| JP2005531495A (ja) | 2005-10-20 |
| EP1455763A1 (de) | 2004-09-15 |
| WO2003055468A1 (en) | 2003-07-10 |
| AU2002364212A1 (en) | 2003-07-15 |
| EP1455763A4 (de) | 2006-01-18 |
| DE60222803T2 (de) | 2008-07-17 |
| CA2466868C (en) | 2010-06-22 |
| EP1455763B1 (de) | 2007-10-03 |
| ES2294197T3 (es) | 2008-04-01 |
| AU2002364212B2 (en) | 2007-09-20 |
| US20030124182A1 (en) | 2003-07-03 |
| US7011846B2 (en) | 2006-03-14 |
| CA2466868A1 (en) | 2003-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60222803D1 (de) | Orale kapselformulierung mit verbesserter physikalischer stabilität | |
| PT750495E (pt) | Utilizacao de um surfactante lipofilico numa composicao farmaceutica | |
| NO20000467L (no) | Farmasøytisk preparat i form av en selvemulgerende formulering for lipofile forbindelser | |
| EE200300235A (et) | Ravimpreparaat, milles aktiivne ingredient on ühtlaselt dispergeeritud abiainete alussegus, ning seda sisaldav doseerimisvorm | |
| EP1337249A4 (de) | Zusammensetzungen und verfahren zur verabreichung von pharmakologisch aktiven verbindungen | |
| HK40583A (en) | Nifedipine-containing solid preparation composition | |
| CO4940469A1 (es) | Composicion oral de estabilidad mejorada que comprende un derivado de indolinona y una mezcla de gliceridos o esteres de polietilenglicol | |
| MX373796B (es) | Composición de solubilización farmacéuticamente aceptable y forma de dosificación farmacéutica que contiene la misma. | |
| BR0215184A (pt) | composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada | |
| LV11884A (lv) | Ciklosporina oralas arstnieciskas formas ar augstu biopieejamibu | |
| WO2001074331A1 (en) | Oily compositions containing highly fat-soluble drugs | |
| DK1173153T3 (da) | Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler | |
| UY26303A1 (es) | Composiciones farmacéuticas para administración oral y tópica | |
| DE69421366D1 (de) | Staurosporinderivate und Polyalkylenglykol-Glyceride enthaltende Arzneimittel | |
| PT92647A (pt) | Processo para a preparacao de 5-cloro-2-< { (3,4-dimetoxi-2-piridinil)-metil}-sulfinil>-1h-benzimidazol e de composicoes farmaceuticas que o contem | |
| YU17899A (sh) | Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu | |
| BR9706804A (pt) | Preparações de cápsula macia contendo ciclosporina. | |
| IT1284604B1 (it) | Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva | |
| DE69325236D1 (de) | Pharmazeutische Zusammensetzungen enthaltend Urodeoxycholicsäure | |
| PE10396A1 (es) | Formulacion farmaceutica administrada oralmente | |
| RU98113920A (ru) | Производные олигопептидов, содержащие d-алкилтриптофан и способные активировать высвобождение гормона роста | |
| DK1009380T3 (da) | Fremgangsmåde til fremstilling af farmaceutiske formuleringer | |
| PT1078627E (pt) | Formulacao farmaceutica compreendendo amoxicilina e clavulanato | |
| NO303526B1 (no) | FremgangsmÕte for fremstilling av et farmas°ytisk preparat inneholdende probukol med forh°yet biotilgjengelighet | |
| WO2002011709A3 (de) | Pharmazeutische, ramipril enthaltende brauseformulierung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |